;PMID: 8152300
;source_file_687.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:39..122] = [t:39..122]
;2)section:[e:126..184] = [t:126..184]
;3)section:[e:188..288] = [t:188..288]
;4)sentence:[e:292..742] = [t:292..742]
;5)sentence:[e:743..964] = [t:743..964]
;6)sentence:[e:965..1142] = [t:965..1142]
;7)sentence:[e:1143..1325] = [t:1143..1325]
;8)sentence:[e:1326..1419] = [t:1326..1419]
;9)sentence:[e:1420..1495] = [t:1420..1495]
;10)sentence:[e:1496..1726] = [t:1496..1726]
;11)section:[e:1730..1774] = [t:1730..1774]

;section 0 Span:0..34
;Leukemia  1994 Apr;8 Suppl 1:S27-9
(SEC
  (FRAG (NNP:[0..8] Leukemia) (CD:[10..14] 1994) (.:[15..20] Apr;8)
        (NNP:[21..26] Suppl) (NNP:[27..32] 1:S27) (::[32..33] -) (CD:[33..34] 9)))

;sentence 1 Span:39..122
;Molecular mechanisms of tumor progression in chronic myeloproliferative 
;disorders.
;[84..121]:malignancy:"chronic myeloproliferative  disorders"
(SENT
  (NP-HLN
    (NP (JJ:[39..48] Molecular) (NNS:[49..59] mechanisms))
    (PP (IN:[60..62] of)
      (NP (NN:[63..68] tumor) (NN:[69..80] progression)))
    (PP (IN:[81..83] in)
      (NP (JJ:[84..91] chronic) (JJ:[92..110] myeloproliferative)
          (NNS:[112..121] disorders)))
    (.:[121..122] .)))

;section 2 Span:126..184
;Gaidano G, Guerrasio A, Serra A, Rege-Cambrin G, Saglio G.
(SEC
  (FRAG (NNP:[126..133] Gaidano) (NNP:[134..135] G) (,:[135..136] ,)
        (NNP:[137..146] Guerrasio) (NNP:[147..148] A) (,:[148..149] ,)
        (NNP:[150..155] Serra) (NNP:[156..157] A) (,:[157..158] ,)
        (NNP:[159..163] Rege) (::[163..164] -) (NNP:[164..171] Cambrin)
        (NNP:[172..173] G) (,:[173..174] ,) (NNP:[175..181] Saglio)
        (NNP:[182..184] G.)))

;section 3 Span:188..288
;Department of Pathology, College of Physicians & Surgeons, Columbia
;University,  New York, NY 10032.
(SEC
  (FRAG (NNP:[188..198] Department) (IN:[199..201] of)
        (NNP:[202..211] Pathology) (,:[211..212] ,) (NNP:[213..220] College)
        (IN:[221..223] of) (NNP:[224..234] Physicians) (CC:[235..236] &)
        (NNP:[237..245] Surgeons) (,:[245..246] ,) (NNP:[247..255] Columbia)
        (NNP:[256..266] University) (,:[266..267] ,) (NNP:[269..272] New)
        (NNP:[273..277] York) (,:[277..278] ,) (NNP:[279..281] NY)
        (CD:[282..287] 10032) (.:[287..288] .)))

;sentence 4 Span:292..742
;We have investigated the involvement of tumor suppressor genes (p53 and RB1)
;and  dominantly acting oncogenes (Ras family genes) in BCR/ABL positive and
;negative  chronic myeloproliferative disorders (CMPD) at different stages of
;the disease,  including 26 cases of BCR/ABL+ chronic myeloid leukemia (CML)
;blast crisis, 9  myelosclerosis with myeloid metaplasia, 4 polycythemia vera,
;10 essential  thrombocythemia, 1 juvenile CML, and 8 BCR/ABL- CML.
;[356..359]:gene-rna:"p53"
;[364..367]:gene-rna:"RB1"
;[403..406]:gene-rna:"Ras"
;[424..440]:malignancy:"BCR/ABL positive"
;[424..431]:variation-event:"BCR/ABL"
;[424..427]:gene-rna:"BCR"
;[428..431]:gene-rna:"ABL"
;[445..453]:malignancy:"negative"
;[455..491]:malignancy:"chronic myeloproliferative disorders"
;[493..497]:malignancy:"CMPD"
;[558..610]:malignancy:"BCR/ABL+ chronic myeloid leukemia (CML) blast crisis"
;[558..565]:variation-event:"BCR/ABL"
;[558..561]:gene-rna:"BCR"
;[562..565]:gene-rna:"ABL"
;[635..653]:malignancy:"myeloid metaplasia"
;[657..674]:malignancy:"polycythemia vera"
;[679..705]:malignancy:"essential  thrombocythemia"
;[709..721]:malignancy:"juvenile CML"
;[729..741]:malignancy:"BCR/ABL- CML"
;[729..736]:variation-event:"BCR/ABL"
;[729..732]:gene-rna:"BCR"
;[733..736]:gene-rna:"ABL"
(SENT
  (S
    (NP-SBJ (PRP:[292..294] We))
    (VP (VBP:[295..299] have)
      (VP (VBN:[300..312] investigated)
        (NP
          (NP (DT:[313..316] the) (NN:[317..328] involvement))
          (PP (IN:[329..331] of)
            (NP
              (NP (NN:[332..337] tumor) (NN:[338..348] suppressor)
                  (NNS:[349..354] genes)
                (PRN (-LRB-:[355..356] -LRB-)
                  (NP (NN:[356..359] p53) (CC:[360..363] and)
                      (NN:[364..367] RB1))
                  (-RRB-:[367..368] -RRB-)))
              (CC:[369..372] and)
              (NP
                (ADJP (RB:[374..384] dominantly) (VBG:[385..391] acting))
                (NNS:[392..401] oncogenes)
                (PRN (-LRB-:[402..403] -LRB-)
                  (NP (NN:[403..406] Ras) (NN:[407..413] family)
                      (NNS:[414..419] genes))
                  (-RRB-:[419..420] -RRB-)))))
          (PP (IN:[421..423] in)
            (NP
              (NP
                (ADJP
                  (NML-2 (NN:[424..427] BCR) (SYM:[427..428] /)
                         (NN:[428..431] ABL))
                  (JJ:[432..440] positive))
                (NML-1 (-NONE-:[440..440] *P*)))
              (CC:[441..444] and)
              (NP
                (ADJP
                  (NML-2 (-NONE-:[444..444] *P*))
                  (JJ:[445..453] negative))
                (NML-1
                  (NML (JJ:[455..462] chronic)
                       (JJ:[463..481] myeloproliferative)
                       (NNS:[482..491] disorders))
                  (NML (-LRB-:[492..493] -LRB-) (NN:[493..497] CMPD)
                       (-RRB-:[497..498] -RRB-)))))))
        (PP (IN:[499..501] at)
          (NP
            (NP (JJ:[502..511] different) (NNS:[512..518] stages))
            (PP (IN:[519..521] of)
              (NP (DT:[522..525] the) (NN:[526..533] disease)))
            (,:[533..534] ,)
            (PP (VBG:[536..545] including)
              (NP
                (NP
                  (NP (CD:[546..548] 26) (NNS:[549..554] cases))
                  (PP (IN:[555..557] of)
                    (NP
                      (ADJP
                        (NML (NN:[558..561] BCR) (SYM:[561..562] /)
                             (NN:[562..565] ABL))
                        (SYM:[565..566] +))
                      (NML
                        (NML (JJ:[567..574] chronic) (JJ:[575..582] myeloid)
                             (NN:[583..591] leukemia))
                        (NML (-LRB-:[592..593] -LRB-) (NN:[593..596] CML)
                             (-RRB-:[596..597] -RRB-)))
                      (NN:[598..603] blast) (NN:[604..610] crisis))))
                (,:[610..611] ,)
                (NP
                  (NP (CD:[612..613] 9) (NN:[615..629] myelosclerosis))
                  (PP (IN:[630..634] with)
                    (NP (JJ:[635..642] myeloid) (NN:[643..653] metaplasia))))
                (,:[653..654] ,)
                (NP (CD:[655..656] 4)
                   (NN:[657..669] polycythemia) (NN:[670..674] vera))
                (,:[674..675] ,)
                (NP (CD:[676..678] 10)
                   (JJ:[679..688] essential) (NN:[690..705] thrombocythemia))
                (,:[705..706] ,)
                (NP (CD:[707..708] 1)
                   (JJ:[709..717] juvenile) (NN:[718..721] CML))
                (,:[721..722] ,) (CC:[723..726] and)
                (NP (CD:[727..728] 8)
                  
                  (ADJP
                    (NML (NN:[729..732] BCR) (SYM:[732..733] /)
                         (NN:[733..736] ABL))
                    (SYM:[736..737] -))
                  (NN:[738..741] CML))))))))
    (.:[741..742] .)))

;sentence 5 Span:743..964
;The presence of mutations  in p53 exons 5 through 9, as well as in RB1 exons
;10-27 and in N-, K-, H-Ras  exons 1 and 2 was tested by the PCR-Single Strand
;Conformation Polymorphism  technique and by PCR-Direct Sequencing.
;[759..768]:variation-event:"mutations"
;[773..776]:gene-rna:"p53"
;[777..794]:variation-location:"exons 5 through 9"
;[810..813]:gene-rna:"RB1"
;[814..825]:variation-location:"exons 10-27"
;[833..835]...[843..846]:gene-rna:"N-"..."Ras"
;[837..839]...[843..846]:gene-rna:"K-"..."Ras"
;[841..846]:gene-rna:"H-Ras"
;[848..855]:variation-location:"exons 1"
;[848..853]...[860..861]:variation-location:"exons"..."2"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[743..746] The) (NN:[747..755] presence))
      (PP (IN:[756..758] of)
        (NP
          (NP (NNS:[759..768] mutations))
          (PP-LOC
            (PP (IN:[770..772] in)
              (NP
                (NP
                  (NML-4 (NN:[773..776] p53))
                  (NML-3 (NNS:[777..782] exons))
                  (CD:[783..784] 5))
                (PP (IN:[785..792] through)
                  (NP
                    (NML-4 (-NONE-:[792..792] *P*))
                    (NML-3 (-NONE-:[792..792] *P*))
                    (CD:[793..794] 9)))))
            (,:[794..795] ,)
            (CONJP (RB:[796..798] as) (RB:[799..803] well) (IN:[804..806] as))
            (PP
              (PP (IN:[807..809] in)
                (NP
                  (NP
                    (NML-6 (NN:[810..813] RB1))
                    (NML-5 (NNS:[814..819] exons))
                    (CD:[820..822] 10))
                  (PP (HYPH:[822..823] -)
                    (NP
                      (NML-6 (-NONE-:[823..823] *P*))
                      (NML-5 (-NONE-:[823..823] *P*))
                      (CD:[823..825] 27)))))
              (CC:[826..829] and)
              (PP (IN:[830..832] in)
                (NP
                  (NML
                    (NML (NN:[833..834] N) (HYPH:[834..835] -)
                      (NML-1 (-NONE-:[835..835] *P*)))
                    (,:[835..836] ,)
                    (NML (NN:[837..838] K) (HYPH:[838..839] -)
                      (NML-1 (-NONE-:[839..839] *P*)))
                    (,:[839..840] ,)
                    (NML (NN:[841..842] H) (HYPH:[842..843] -)
                      (NML-1 (NN:[843..846] Ras))))
                  (NML
                    (NML
                      (NML-7 (NNS:[848..853] exons))
                      (CD:[854..855] 1))
                    (CC:[856..859] and)
                    (NML
                      (NML-7 (-NONE-:[859..859] *P*))
                      (CD:[860..861] 2))))))))))
    (VP (VBD:[862..865] was)
      (VP (VBN:[866..872] tested)
        (NP-2 (-NONE-:[872..872] *))
        (PP-MNR
          (PP (IN:[873..875] by)
            (NP (DT:[876..879] the)
              (NML (NN:[880..883] PCR) (HYPH:[883..884] -)
                (NML (JJ:[884..890] Single) (NN:[891..897] Strand))
                (NN:[898..910] Conformation) (NN:[911..923] Polymorphism))
              (NN:[925..934] technique)))
          (CC:[935..938] and)
          (PP (IN:[939..941] by)
            (NP (NN:[942..945] PCR) (HYPH:[945..946] -) (JJ:[946..952] Direct)
                (NN:[953..963] Sequencing))))))
    (.:[963..964] .)))

;sentence 6 Span:965..1142
;In addition, Southern blot analysis was  used to investigate the occurrence
;of gross rearrangements in the p53 gene as  well as loss of heterozygosity at
;17p13, the site of p53.
;[1050..1064]:variation-type:"rearrangements"
;[1072..1075]:gene-rna:"p53"
;[1093..1115]:variation-type:"loss of heterozygosity"
;[1119..1124]:variation-location:"17p13"
;[1138..1141]:gene-rna:"p53"
(SENT
  (S
    (PP (IN:[965..967] In)
      (NP (NN:[968..976] addition)))
    (,:[976..977] ,)
    (NP-SBJ-1
      (NML (JJ:[978..986] Southern) (NN:[987..991] blot))
      (NN:[992..1000] analysis))
    (VP (VBD:[1001..1004] was)
      (VP (VBN:[1006..1010] used)
        (NP-1 (-NONE-:[1010..1010] *))
        (S-PRP
          (NP-SBJ (-NONE-:[1010..1010] *))
          (VP (TO:[1011..1013] to)
            (VP (VB:[1014..1025] investigate)
              (NP
                (NP
                  (NP (DT:[1026..1029] the) (NN:[1030..1040] occurrence))
                  (PP (IN:[1041..1043] of)
                    (NP
                      (NP (JJ:[1044..1049] gross)
                          (NNS:[1050..1064] rearrangements))
                      (PP-LOC (IN:[1065..1067] in)
                        (NP (DT:[1068..1071] the) (NN:[1072..1075] p53)
                            (NN:[1076..1080] gene))))))
                (CONJP (RB:[1081..1083] as) (RB:[1085..1089] well)
                       (IN:[1090..1092] as))
                (NP
                  
                  (NP (NN:[1093..1097] loss))
                  (PP (IN:[1098..1100] of)
                    (NP (NN:[1101..1115] heterozygosity)))
                  (PP-LOC (IN:[1116..1118] at)
                    (NP
                      (NP (NN:[1119..1124] 17p13))
                      (,:[1124..1125] ,)
                      (NP
                        (NP (DT:[1126..1129] the) (NN:[1130..1134] site))
                        (PP (IN:[1135..1137] of)
                          (NP (NN:[1138..1141] p53)))))))))))))
    (.:[1141..1142] .)))

;sentence 7 Span:1143..1325
;Acute phase  BCR/ABL-CMPD cases displayed a high frequency of p53 (2/7) and
;Ras (3/7)  lesions, whereas BCR/ABL- CMPD in chronic phase displayed only
;germline p53 and  Ras sequences.
;[1156..1168]:malignancy:"BCR/ABL-CMPD"
;[1156..1163]:variation-event:"BCR/ABL"
;[1156..1159]:gene-rna:"BCR"
;[1160..1163]:gene-rna:"ABL"
;[1205..1208]:gene-rna:"p53"
;[1219..1222]:gene-rna:"Ras"
;[1247..1277]:malignancy:"BCR/ABL- CMPD in chronic phase"
;[1247..1254]:variation-event:"BCR/ABL"
;[1247..1250]:gene-rna:"BCR"
;[1251..1254]:gene-rna:"ABL"
;[1302..1305]:gene-rna:"p53"
;[1311..1314]:gene-rna:"Ras"
(SENT
  (S
    (NP-SBJ
      (NML (JJ:[1143..1148] Acute) (NN:[1149..1154] phase))
      (NML
        (ADJP
          (NML (NN:[1156..1159] BCR) (SYM:[1159..1160] /) (NN:[1160..1163] ABL))
          (SYM:[1163..1164] -))
        (NN:[1164..1168] CMPD))
      (NNS:[1169..1174] cases))
    (VP (VBD:[1175..1184] displayed)
      (NP
        (NP (DT:[1185..1186] a) (JJ:[1187..1191] high)
            (NN:[1192..1201] frequency))
        (PP (IN:[1202..1204] of)
          (NP
            (NP (NN:[1205..1208] p53)
              (PRN (-LRB-:[1209..1210] -LRB-)
                (NP
                  (NP (CD:[1210..1211] 2))
                  (PP (SYM:[1211..1212] /)
                    (NP (CD:[1212..1213] 7))))
                (-RRB-:[1213..1214] -RRB-))
              (NML-3 (-NONE-:[1214..1214] *P*)))
            (CC:[1215..1218] and)
            (NP (NN:[1219..1222] Ras)
              (PRN (-LRB-:[1223..1224] -LRB-)
                (NP
                  (NP (CD:[1224..1225] 3))
                  (PP (SYM:[1225..1226] /)
                    (NP (CD:[1226..1227] 7))))
                (-RRB-:[1227..1228] -RRB-))
              (NML-3 (NNS:[1230..1237] lesions))))))
      (,:[1237..1238] ,)
      (SBAR-ADV (IN:[1239..1246] whereas)
        (S
          (NP-SBJ
            (NP
              (ADJP
                (NML (NN:[1247..1250] BCR) (SYM:[1250..1251] /)
                     (NN:[1251..1254] ABL))
                (SYM:[1254..1255] -))
              (NN:[1256..1260] CMPD))
            (PP (IN:[1261..1263] in)
              (NP (JJ:[1264..1271] chronic) (NN:[1272..1277] phase))))
          (VP (VBD:[1278..1287] displayed)
            (NP (JJ:[1288..1292] only)
              (NML
                (NML
                  (NML-2 (NN:[1293..1301] germline))
                  (NN:[1302..1305] p53)
                  (NML-1 (-NONE-:[1305..1305] *P*)))
                (CC:[1306..1309] and)
                (NML
                  (NML-2 (-NONE-:[1309..1309] *P*))
                  (NN:[1311..1314] Ras)
                  (NML-1 (NNS:[1315..1324] sequences)))))))))
    (.:[1324..1325] .)))

;sentence 8 Span:1326..1419
;Conversely, p53 inactivation was restricted to only 1/26 cases of  BCR/ABL+
;CML blast crisis.
;[1338..1341]:gene-rna:"p53"
;[1393..1418]:malignancy:"BCR/ABL+ CML blast crisis"
;[1393..1400]:variation-event:"BCR/ABL"
;[1393..1396]:gene-rna:"BCR"
;[1397..1400]:gene-rna:"ABL"
(SENT
  (S
    (ADVP (RB:[1326..1336] Conversely))
    (,:[1336..1337] ,)
    (NP-SBJ-1 (NN:[1338..1341] p53) (NN:[1342..1354] inactivation))
    (VP (VBD:[1355..1358] was)
      (VP (VBN:[1359..1369] restricted)
        (NP-1 (-NONE-:[1369..1369] *))
        (PP (TO:[1370..1372] to)
          (NP
            (NP (RB:[1373..1377] only) (CD:[1378..1379] 1))
            (PP (SYM:[1379..1380] /)
              (NP
                (NP (CD:[1380..1382] 26) (NNS:[1383..1388] cases))
                (PP (IN:[1389..1391] of)
                  (NP
                    (NML
                      (ADJP
                        (NML (NN:[1393..1396] BCR) (SYM:[1396..1397] /)
                             (NN:[1397..1400] ABL))
                        (SYM:[1400..1401] +))
                      (NN:[1402..1405] CML))
                    (NN:[1406..1411] blast) (NN:[1412..1418] crisis)))))))))
    (.:[1418..1419] .)))

;sentence 9 Span:1420..1495
;No alterations in the RB1 gene were detected in any  of the cases analyzed.
;[1442..1445]:gene-rna:"RB1"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1420..1422] No) (NNS:[1423..1434] alterations))
      (PP (IN:[1435..1437] in)
        (NP (DT:[1438..1441] the) (NN:[1442..1445] RB1) (NN:[1446..1450] gene))))
    (VP (VBD:[1451..1455] were)
      (VP (VBN:[1456..1464] detected)
        (NP-1 (-NONE-:[1464..1464] *))
        (PP (IN:[1465..1467] in)
          (NP
            (NP (DT:[1468..1471] any))
            (PP (IN:[1473..1475] of)
              (NP
                (NP (DT:[1476..1479] the) (NNS:[1480..1485] cases))
                (VP (VBN:[1486..1494] analyzed)
                  (NP (-NONE-:[1494..1494] *)))))))))
    (.:[1494..1495] .)))

;sentence 10 Span:1496..1726
;These data indicate that p53 inactivation and/or Ras  activation might play a
;role in acute transformation of BCR/ABL- CMPD and that  the molecular
;mechanisms of tumor progression may be different in BCR/ABL+  versus
;BCR/ABL-CMPD.
;[1521..1524]:gene-rna:"p53"
;[1545..1548]:gene-rna:"Ras"
;[1606..1619]:malignancy:"BCR/ABL- CMPD"
;[1606..1613]:variation-event:"BCR/ABL"
;[1606..1609]:gene-rna:"BCR"
;[1610..1613]:gene-rna:"ABL"
;[1696..1704]:malignancy:"BCR/ABL+"
;[1696..1703]:variation-event:"BCR/ABL"
;[1696..1699]:gene-rna:"BCR"
;[1700..1703]:gene-rna:"ABL"
;[1713..1725]:malignancy:"BCR/ABL-CMPD"
;[1713..1720]:variation-event:"BCR/ABL"
;[1713..1716]:gene-rna:"BCR"
;[1717..1720]:gene-rna:"ABL"
;[1721..1725]:malignancy:"CMPD"
(SENT
  (S
    (NP-SBJ (DT:[1496..1501] These) (NNS:[1502..1506] data))
    (VP (VBP:[1507..1515] indicate)
      (SBAR
        (SBAR (IN:[1516..1520] that)
          (S
            (NP-SBJ
              (NP (NN:[1521..1524] p53) (NN:[1525..1537] inactivation))
              (CC:[1538..1544] and/or)
              (NP (NN:[1545..1548] Ras) (NN:[1550..1560] activation)))
            (VP (MD:[1561..1566] might)
              (VP (VB:[1567..1571] play)
                (NP (DT:[1572..1573] a) (NN:[1574..1578] role))
                (PP (IN:[1579..1581] in)
                  (NP
                    (NP (JJ:[1582..1587] acute) (NN:[1588..1602] transformation))
                    (PP (IN:[1603..1605] of)
                      (NP
                        (ADJP
                          (NML (NN:[1606..1609] BCR) (SYM:[1609..1610] /)
                               (NN:[1610..1613] ABL))
                          (SYM:[1613..1614] -))
                        (NN:[1615..1619] CMPD)))))))))
        (CC:[1620..1623] and)
        (SBAR (IN:[1624..1628] that)
          (S
            (NP-SBJ
              (NP (DT:[1630..1633] the) (JJ:[1634..1643] molecular)
                  (NNS:[1644..1654] mechanisms))
              (PP (IN:[1655..1657] of)
                (NP (NN:[1658..1663] tumor) (NN:[1664..1675] progression))))
            (VP (MD:[1676..1679] may)
              (VP (VB:[1680..1682] be)
                (ADJP-PRD (JJ:[1683..1692] different)
                  (PP (IN:[1693..1695] in)
                    (NP
                      (NP
                        (ADJP
                          (NML (NN:[1696..1699] BCR) (SYM:[1699..1700] /)
                               (NN:[1700..1703] ABL))
                          (SYM:[1703..1704] +))
                        (NML-1 (-NONE-:[1704..1704] *P*)))
                      (IN:[1706..1712] versus)
                      (NP
                        (ADJP
                          (NML (NN:[1713..1716] BCR) (SYM:[1716..1717] /)
                               (NN:[1717..1720] ABL))
                          (SYM:[1720..1721] -))
                        (NML-1 (NN:[1721..1725] CMPD))))))))))))
    (.:[1725..1726] .)))

;section 11 Span:1730..1774
;PMID: 8152300 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1730..1734] PMID) (::[1734..1735] :) (CD:[1736..1743] 8152300)
        (NN:[1744..1745] -LSB-) (NNP:[1745..1751] PubMed) (::[1752..1753] -)
        (NN:[1754..1761] indexed) (IN:[1762..1765] for)
        (NNP:[1766..1774] MEDLINE-RSB-)))
